Abhängigkeit des symptomfreien Überlebens 5-FU behandelter Darmkrebspatienten vom Verhältnis der mRNA-Expressionshöhe aus Thymidinphosphorylase und Dihydropyrimidindehydrogenase

The present invention is directed to a method for determining whether a patient suffering from cancer is susceptable to a treatment with a 5-Fluoro-Uracil analogon comprising a) determination of Thymidine Phosphorylase mRNA expression in a clinical sample, b) determination of Dihydropyrimindine Dehy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	POIGNEE, MANUELA, KRAUSE, FRIEDMANN, LASSMANN, SILKE, WERNER, MARTIN, DR, PORSTMANN, BAERBEL, DR, LUTZ, VERENA, WALTER, THOMAS
Format:	Patent
Sprache:	ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention is directed to a method for determining whether a patient suffering from cancer is susceptable to a treatment with a 5-Fluoro-Uracil analogon comprising a) determination of Thymidine Phosphorylase mRNA expression in a clinical sample, b) determination of Dihydropyrimindine Dehydrogenase mRNA expression in said clinical sample, and c) determination of the ratio of the value obtained in step a) and the value obtained in step b). If the ratio exceeds a certain cut off, susceptability to 5-FU and/or 5-FU analoga can be expected.